Navigation Links
New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
Date:11/16/2011

ORLANDO, Fla., Nov. 16, 2011 /PRNewswire/ -- An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient® (prasugrel) on cardiovascular (CV) events (CV death, myocardial infarction [MI] and stroke) compared to clopidogrel relative to the timing of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with ST-segment elevation myocardial infarction (STEMI).(1)

At 15 months, primary PCI patients with STEMI had an 11 percent relative risk reduction in CV events, and secondary PCI patients had a 35 percent relative risk reduction with Effient compared to clopidogrel (HR 0.89, 95% CI 0.69-1.13; and HR 0.65, 95% CI 0.46-0.93, respectively).  Absolute risk reduction for Effient compared to clopidogrel was 1.3 percent for the primary PCI group and 4.6 percent for the secondary PCI group.(1)

"Not all ST-elevation MI patients are treated with primary PCI; therefore, understanding the effects of more potent inhibition of platelets in ACS patients who are treated with primary PCI or those treated with delayed PCI is important for choosing antiplatelet therapies," said lead author Jacob A. Udell, MD, MPH, Clinical Fellow, Cardiovascular Medicine, Brigham & Women's Hospital. "These data demonstrate that efficacy and bleeding rates for Effient are consistent with the overall TRITON-TIMI 38 trial results irrespective of when STEMI patients undergo intended PCI."

In the study, primary PCI was defined as PCI within 12 hours from onset of acute coronary syndrome (ACS) symptoms and secondary PCI was defined as PCI more than 12 hours after initial onset or initial medical therapy. Of the 3,534 STEMI patients from the TRITON-TIMI 38 trial who were included in this analysis, 2,340 (68 percent) underwent primary PCI and 1,085 underwent secondary PCI. Randomization to Effient or clopidogrel occurred at presentati
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Triple Analysis: Leukemia, Cancer Vaccines and Peptides
2. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
3. PRA Early Phase Experts to Speak at Bioanalysis Conference
4. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
5. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
6. Turkey Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2017
7. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
8. Molecular Devices, LLC Introduces SoftMax Pro® 6 Microplate Data Acquisition and Analysis Software With Powerful New Data Analysis and Reporting Features
9. Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
10. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
11. Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... HOUSTON, TX and VANCOUVER , ... the "Company") (TSX-V: EPI) announced today that its common shares ... Capital Market ("NASDAQ") under the symbol "EPIX". ESSA ... Company will retain its listing on the TSX Venture Exchange ... the listing of the common shares on the NASDAQ, each ...
(Date:7/2/2015)... , July 2, 2015  Fort Lauderdale-based ... pleased to announce that its Consumer Group completed ... to Kerry Group plc (ISE: KRZ) ("Kerry"), one ... and nutrition systems, as well as functional ingredients ... pharmaceutical markets. Farlie Turner served as the exclusive ...
(Date:7/2/2015)... July 2, 2015 Roche,s Bloodhound technology ... market segment in hematology testing, according to Kalorama ... recent unveiling of its Bloodhound digital cell imaging ... m 511 hematology analyzer – is notable ... enjoyed by current leader CellaVision, but also compete ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first ... and athletic trainers. Their significant popularity has inspired four new, fun shades including: ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company , announced today that it has reached an agreement to acquire ... CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Octo Consulting Group, (Octo), a ... government, has announced they are among nine contractors awarded the U.S. Securities and ... contract not to exceed $250 million. , To achieve the goals of ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3
... Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of ... the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be ... Hawaii. , , , ... 2009 Pan Pacific Lymphoma Conference, ...
... , , , President Obama Calls For Health ... 15 The American Medical Association warmly welcomed U.S. ... Like the president, the AMA is committed to health reform this ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , ...
... MBA, FACPE, Ameritox,s Senior Vice President and Chief Medical Officer, ... for the American College of Physician Executives (ACPE), a national ... , Dr. Leider became an ACPE member 20 years ... College for 13 years teaching courses on improving the quality ...
... 16, 2009 at 9:00 a.m. Eastern Time , , ... ALXA ) announced today that it has exercised ... Allegro. The purchase of Symphony Allegro, which is subject ... 2009. , , Alexza and Symphony Capital Partners, LP ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... 15, 2009 (BRONX, NY) In a study ... researchers from Albert Einstein College of Medicine of Yeshiva ... HIV-positive individuals are most likely to develop deadly fungal ... of meningitis affects more than 900,000 HIV-infected people globallymost ...
Cached Medicine News:Health News:President Obama Receives Warm Welcome from AMA Physicians 2Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Predicting fatal fungal infections 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: